AR059324A2 - Una forma solida de dosificacion oral - Google Patents

Una forma solida de dosificacion oral

Info

Publication number
AR059324A2
AR059324A2 ARP070100474A ARP070100474A AR059324A2 AR 059324 A2 AR059324 A2 AR 059324A2 AR P070100474 A ARP070100474 A AR P070100474A AR P070100474 A ARP070100474 A AR P070100474A AR 059324 A2 AR059324 A2 AR 059324A2
Authority
AR
Argentina
Prior art keywords
oral dosage
solid oral
solid form
oral dosing
pharmaceutically acceptable
Prior art date
Application number
ARP070100474A
Other languages
English (en)
Inventor
Yoshimitsu Katakuse
Fujiki Yamato
Takashi Taike
Robert Frank Wagner
Manfred Kohlmeyer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059324(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR059324A2 publication Critical patent/AR059324A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma solida de dosificacion oral que comprende: (a) un agente activo que contiene una cantidad efectiva de valsartan o una sal farmacéuticamente aceptable del mismo, y (b) aditivos farmacéuticamente aceptables adecuados para la preparacion de formas solidas de dosificacion oral por métodos de comprension; en donde el agente activo está presente en una cantidad de 45% a 65% en peso basado en el peso total de la forma solida de dosificacion oral.
ARP070100474A 1996-06-27 2007-02-06 Una forma solida de dosificacion oral AR059324A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613470.5A GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form

Publications (1)

Publication Number Publication Date
AR059324A2 true AR059324A2 (es) 2008-03-26

Family

ID=10795969

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970102790A AR008618A1 (es) 1996-06-27 1997-06-25 PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE").
ARP070100474A AR059324A2 (es) 1996-06-27 2007-02-06 Una forma solida de dosificacion oral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970102790A AR008618A1 (es) 1996-06-27 1997-06-25 PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE").

Country Status (33)

Country Link
US (3) US6294197B1 (es)
EP (7) EP1767207A3 (es)
JP (5) JP2000506540A (es)
KR (6) KR101161283B1 (es)
CN (3) CN1951372B (es)
AR (2) AR008618A1 (es)
AT (3) ATE446749T1 (es)
BR (1) BR9709956A (es)
CA (2) CA2259148C (es)
CO (1) CO4870755A1 (es)
CY (1) CY2553B1 (es)
CZ (1) CZ296850B6 (es)
DE (3) DE69739642D1 (es)
DK (3) DK0914119T3 (es)
ES (3) ES2335683T3 (es)
GB (1) GB9613470D0 (es)
HK (2) HK1019858A1 (es)
HU (1) HU229134B1 (es)
ID (1) ID17553A (es)
IL (2) IL127564A0 (es)
MY (3) MY156312A (es)
NO (2) NO317181B1 (es)
NZ (2) NZ333385A (es)
PE (1) PE87498A1 (es)
PL (2) PL188233B1 (es)
PT (3) PT1410797E (es)
RU (5) RU2294743C2 (es)
SI (2) SI1410797T1 (es)
SK (1) SK285902B6 (es)
TR (1) TR199802698T2 (es)
TW (1) TW473394B (es)
WO (1) WO1997049394A2 (es)
ZA (1) ZA975673B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
DK1736144T3 (en) 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
CZ299429B6 (cs) * 1998-07-10 2008-07-23 Novartis Ag Lék obsahující kombinaci valsartanu a blokátoru kalciového kanálu
CA2351357A1 (en) 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
DE60028928T2 (de) * 1999-01-26 2007-01-04 Novartis Ag Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
CA2383252A1 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
DE10066408B4 (de) * 2000-03-24 2010-03-18 3M Espe Dental Ag Verwendung feinkörniger Pulver für supragingivales Pulverstrahlen
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
NZ540748A (en) * 2000-06-22 2007-04-27 Novartis Ag An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1
AU2005200815B2 (en) * 2000-06-22 2008-01-17 Novartis Ag Solid valsartan pharmaceutical compositions
CN1216873C (zh) 2000-07-19 2005-08-31 诺瓦提斯公司 缬沙坦的盐
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2003013609A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1511739B1 (en) * 2003-03-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of valsartan
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
US7378531B2 (en) * 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
WO2005013964A1 (ja) * 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
SK50472005A3 (sk) * 2003-11-03 2005-09-08 Zentiva, A. S. Tableta s obsahom valsartanu vyrobená priamym tabletovaním
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
JP2005187793A (ja) * 2003-12-24 2005-07-14 Rohm & Haas Electronic Materials Llc 改良された接着剤
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
WO2006029056A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Preparation of olmesartan medoxomil
PT2801354T (pt) 2004-10-08 2017-06-05 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
DE602005023193D1 (de) * 2004-10-15 2010-10-07 Suedzucker Ag Verbessertes trommelcoating-verfahren
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
US20080102120A1 (en) * 2004-12-24 2008-05-01 Miha Vrbinc Solid Pharmaceutical Composition Comprising Valsartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
AU2005332300B2 (en) * 2005-05-31 2011-07-07 Mylan Laboratories, Inc. Compositions comprising nebivolol
WO2007005967A2 (en) * 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
WO2007052307A2 (en) * 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
EP2395021A1 (en) 2006-06-06 2011-12-14 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
JP2010508266A (ja) * 2006-10-30 2010-03-18 ハナル ファーマシューティカル カンパニー リミテッド チアジド系化合物およびアンジオテンシン−ii−受容体遮断剤を含む放出性が制御された薬学的組成物
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
CA2681708A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
BRPI0815376A2 (pt) * 2007-07-31 2014-10-07 Cargill Inc Dextrose diretamente compresível
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
WO2009045795A2 (en) * 2007-09-28 2009-04-09 Novartis Ag Galenical formulations of aliskiren and valsartan
US20100222334A1 (en) 2007-10-09 2010-09-02 Wayne Talamonti Pharmaceutical Formulation of Valsartan
SI3067043T1 (sl) * 2007-11-06 2023-04-28 Novartis Ag Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
US8785432B2 (en) * 2007-12-31 2014-07-22 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
MX2010009500A (es) * 2008-02-28 2010-09-24 Novartis Ag Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones.
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
EP2281557A4 (en) * 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) * 2008-10-10 2011-05-11 이희엽 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
WO2011027021A1 (en) * 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
KR101084783B1 (ko) * 2009-09-01 2011-11-22 삼성에스디아이 주식회사 이차 전지 및 그의 제조 방법
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja) 2011-03-31 2016-03-09 キヤノン株式会社 振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) * 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
MX2014007933A (es) 2011-12-26 2014-07-30 Novartis Ag Comprimidos y agentes recubiertos en seco.
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンii受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
WO2014038895A1 (ko) * 2012-09-06 2014-03-13 한국콜마주식회사 발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) * 2012-09-21 2014-04-10 Ohara Yakuhin Kogyo Kk バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) * 2014-04-25 2017-11-29 沢井製薬株式会社 バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) * 2016-03-02 2017-06-07 大原薬品工業株式会社 バルサルタン含有錠剤の製造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US11081240B2 (en) 2018-06-14 2021-08-03 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200039A (en) 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en) 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
AU528098B2 (en) 1978-11-16 1983-04-14 Beecham Group Plc Analgesic tablet
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) * 1979-10-29 1980-12-09 Merck & Co., Inc. Novel pharmaceutical compositions
EP0070127A3 (en) 1981-07-10 1983-08-17 Beecham Group Plc Tablets
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) * 1986-10-17 1988-05-10 Berlex Laboratories, Inc. Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) * 1987-02-18 1988-09-01 Boehringer Ingelheim Kg Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) * 1987-06-19 1996-07-31 旭化成工業株式会社 固形製剤の製法
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
SE506179C2 (sv) * 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
EP0443983B1 (de) * 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
CA2092565A1 (en) * 1990-09-28 1992-03-29 Robert T. Sims Ibuprofen-diuretic combinations
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
IL104755A0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
AU5745394A (en) 1992-12-30 1994-08-15 Fmc Corporation Readily available konjac glucomannan sustained release excipient
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンii介在性諸疾患の予防または治療剤
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
GB9404010D0 (en) * 1994-03-02 1994-04-20 Opt Tel Services Limited Telephone dialling monitoring and route selecting apparatus
HUT76542A (en) 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE19502065C2 (de) * 1995-01-14 1996-05-02 Prophyta Biolog Pflanzenschutz Pilzisolat mit fungizider Wirkung
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
JP2011123241A (ja) * 2009-12-10 2011-06-23 Canon Inc 撮影システム

Also Published As

Publication number Publication date
JP2014012747A (ja) 2014-01-23
WO1997049394A3 (en) 2001-12-20
JP4969338B2 (ja) 2012-07-04
PT914119E (pt) 2005-02-28
RU2013113610A (ru) 2014-10-10
RU2007100200A (ru) 2008-07-20
KR101208430B1 (ko) 2012-12-05
TW473394B (en) 2002-01-21
HUP0203374A2 (hu) 2004-05-28
US6485745B1 (en) 2002-11-26
PE87498A1 (es) 1998-12-21
EP1776953A1 (en) 2007-04-25
PL188271B1 (pl) 2005-01-31
ZA975673B (en) 1997-12-29
CN1951372A (zh) 2007-04-25
PL330709A1 (en) 1999-05-24
KR100618038B1 (ko) 2006-11-30
CZ296850B6 (cs) 2006-07-12
AU724998B2 (en) 2000-10-05
CA2259148A1 (en) 1997-12-31
AU3340297A (en) 1998-01-14
CY2553B1 (en) 2008-07-02
ATE446749T1 (de) 2009-11-15
DE69738089D1 (de) 2007-10-11
ES2290400T3 (es) 2008-02-16
BR9709956A (pt) 1999-08-10
US6858228B2 (en) 2005-02-22
DE69738089T2 (de) 2008-05-21
GB9613470D0 (en) 1996-08-28
ID17553A (id) 1998-01-08
NZ524346A (en) 2004-09-24
KR20060079260A (ko) 2006-07-05
SK285902B6 (sk) 2007-10-04
CA2673462C (en) 2011-10-04
CA2673462A1 (en) 1997-12-31
JP2003231634A (ja) 2003-08-19
ATE371449T1 (de) 2007-09-15
RU2294743C2 (ru) 2007-03-10
DK0914119T3 (da) 2005-01-31
DE69730834T2 (de) 2005-10-06
DK1410797T3 (da) 2007-10-15
US6294197B1 (en) 2001-09-25
EP1774967A1 (en) 2007-04-18
MY146868A (en) 2012-09-28
WO1997049394A2 (en) 1997-12-31
EP2055301A1 (en) 2009-05-06
HK1019858A1 (en) 2000-06-09
CO4870755A1 (es) 1999-12-27
PT1410797E (pt) 2007-12-03
NO986056D0 (no) 1998-12-22
CN1951372B (zh) 2011-03-23
RU2203054C2 (ru) 2003-04-27
EP1767206B1 (en) 2009-10-28
KR20080014149A (ko) 2008-02-13
SI1410797T1 (sl) 2008-08-31
RU2453306C2 (ru) 2012-06-20
DK1767206T3 (da) 2010-01-25
ES2231873T3 (es) 2005-05-16
KR20050092054A (ko) 2005-09-16
EP1410797B1 (en) 2007-08-29
EP0914119A2 (en) 1999-05-12
KR101161283B1 (ko) 2012-07-02
DE69739642D1 (de) 2009-12-10
CN1133427C (zh) 2004-01-07
EP1767206A3 (en) 2007-04-18
EP0914119A3 (en) 2002-03-06
JP2007238637A (ja) 2007-09-20
EP1410797A1 (en) 2004-04-21
HK1060700A1 (en) 2004-08-20
CZ426998A3 (cs) 1999-03-17
NO331739B1 (no) 2012-03-12
KR100792389B1 (ko) 2008-01-08
CN1232394A (zh) 1999-10-20
EP1767207A2 (en) 2007-03-28
JP2000506540A (ja) 2000-05-30
MY123149A (en) 2006-05-31
NO317181B1 (no) 2004-09-06
HUP0203374A3 (en) 2004-06-28
DE69730834D1 (de) 2004-10-28
EP1767207A3 (en) 2007-04-18
JP2012051948A (ja) 2012-03-15
HU229134B1 (en) 2013-08-28
CN1475207A (zh) 2004-02-18
PL188233B1 (pl) 2004-12-31
AR008618A1 (es) 2000-02-09
EP1767206A2 (en) 2007-03-28
RU2009115778A (ru) 2010-11-10
TR199802698T2 (xx) 1999-04-21
NO20041287L (no) 2004-03-26
NO986056L (no) 1998-12-22
IL195339A0 (en) 2009-08-03
ATE276750T1 (de) 2004-10-15
US20030035832A1 (en) 2003-02-20
CA2259148C (en) 2009-09-29
MY156312A (en) 2016-01-29
SK178498A3 (en) 1999-06-11
KR20110063587A (ko) 2011-06-10
EP0914119B1 (en) 2004-09-22
NZ333385A (en) 2000-09-29
KR20000022111A (ko) 2000-04-25
ES2335683T3 (es) 2010-03-31
PT1767206E (pt) 2010-01-27
IL127564A0 (en) 1999-10-28
SI0914119T1 (en) 2005-04-30
KR20090099020A (ko) 2009-09-18
CN1475207B (zh) 2010-09-29

Similar Documents

Publication Publication Date Title
AR059324A2 (es) Una forma solida de dosificacion oral
ES2117015T3 (es) Composiciones que contienen sumatriptan.
AR033688A1 (es) Composicion parenteral reconstituible
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
ES2177346T3 (es) Formulaciones de ranolazina de liberacion lenta.
ES2180738T3 (es) Preparaciones solidas de productos activos.
CO4340618A1 (es) Composicion farmaceutica para liberacion controlada
HRP20030046B1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
AR004255A1 (es) Formulacion liofilizada farmaceuticamente aceptable constituida por una fase amorfa y una fase cristalina, que comprende por lo menos un principio activo no proteico, y procedimiento para estabilizar el principio activo no proteico contenido en la formulacion liofilizada farmaceuticamente aceptable
AR022090A1 (es) PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN
AR031682A1 (es) Composiciones farmaceuticas
CO5280073A1 (es) Composiciones
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
AR031067A1 (es) Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma.
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
AR036937A1 (es) Tableta masticable que contiene lisina
ES2125447T3 (es) Composiciones orales para tratar placa y gingivitis que contienen un agente antibacteriano no cationico y una sal bicarbonato.
CO5241355A1 (es) Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
AR042598A1 (es) Composiciones de acetaminofeno

Legal Events

Date Code Title Description
FC Refusal